Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $67.52M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.22M
Average 19.76M
GOSS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Gossamer Bio, Inc.NASDAQ: GOSS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$43.68M, compared with -$33.55M a year earlier. Trailing-twelve-month EBITDA was -$168.81M.
Context
- EBITDA amounted to 326.9% of revenue in FY2025, up 292.1 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$80.49M (+49.2%) for the fiscal year ending Dec 2026, a step up from the -296.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$43.68M+1.5% QoQ
- Last fiscal yearDec 2025
- -$158.47M-296.5% YoY
- LTMMar 2026
- -$168.81M-372.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -30.2% | -74.2% | -44.0 pp |
| 1 year | -296.5% | +49.2% | +345.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (158.47M) USD
- Year-over-year change
- -296.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (158.47M) | -296.5% |
| FY2024 | 2024-12-31 | (39.97M) | +75.3% |
| FY2023 | 2023-12-31 | (161.92M) | +23.3% |
| FY2022 | 2022-12-31 | (211.07M) | -0.8% |
| FY2021 | 2021-12-31 | (209.4M) | — |
EBITDA vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 EBITDA of -$168.81M is the 7th highest of the 9 companies compared; the peer median is -$95.93M.
- Its year-over-year change of -372.8% is the lowest of 8, against a peer median of +3.9%.
- EBITDA amounts to 304.0% of revenue for GOSS, versus a peer median of 115.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $131.28M | +170.9% | — | 43.8% | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$42.27M | -2.3% | — | — | |
| LTM Mar 2026 | -$74.72M | +35.0% | — | 129.0% | |
| LTM Dec 2025 | -$117.15M | — | — | 101.1% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$168.81M | -372.8% | — | 304.0% | |
| LTM Mar 2026 | -$184.67M | -43.8% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| Peer median (excluding GOSS) | -$95.93M | +3.9% | — | 115.0% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| Weighted Avg Shares | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
| Weighted Avg Shares (Diluted) | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.